19 August 2022>: Original Paper
Risk Factors for Erythrocytosis in Renal Transplantation: Is Ganciclovir Therapy One of Them?
Fatma Özge Kayhan Koçak 1ABCDEF* , Musa Bali 2ADEFDOI: 10.12659/AOT.936814
Ann Transplant 2022; 27:e936814
Table 1 Characteristics of patients.
PTE group (n=43) | Non-PTE group (n=142) | P value | |
---|---|---|---|
Male, No. (%) | 39 (90.7%) | 84 (59.2%) | |
Living donor, No (%) | 37 (86%) | 96 (67.6%) | |
Cause of ESRD | |||
Hypertension No. (%) | 11 (25.6%) | 14 (9.9%) | |
MAP, mmHg | 90±12.1 | 94.8±13 | |
Immunosuppressive drug, No. (%) | |||
mTOR | 7 (16.3%) | 15 (10.6%) | 0.31 |
CNI | 36 (83.7%) | 128 (90.1%) | 0.25 |
MMF/azathioprine | 126 (88.7%) | 39 (90.7%) | 0.48 |
ACEi/ARB, No. (%) | 10 (23.3%) | 39 (27.5%) | 0.58 |
CMV prophylaxis, No. (%) | 24 (55.8%) | 54 (38%) | |
GFR (ml/min) | 72±21.6 | 62.5±27.7 | |
ALT | 23.3±10.2 | 18.4±9.4 | |
Calcium | 9.8±0.71 | 9.5±0.58 | |
ESRD – End-Stage Renal Disease; MAP – mean arterial pressure; ACEi/ARB – angiotensin-converting enzyme inhibitor/angiotensinogen receptor blocker; CNI – calcineurin inhibitor; MMF – mycophenolate mofetil; mTORi – mammalian target of rapamycin inhibitor; GFR – glomerular filtration rate; ALT – alanine aminotransferase; CMV – cytomegalovirus. |